XML 25 R10.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Investments | 6 Months Ended
--- | ---
Jun. 30, 2024
Equity Method Investments and Joint Ventures [Abstract] |
Investments | Investments (a)Equity method investments, net A reconciliation of the carrying amount of the investments in equity method investees, net is as follows:
| Ownership interest |  | As of June 30, 2024 |  | As of December 31, 2023
Cronos Growing Company Inc. (“Cronos GrowCo”) | 50% |  | $ | 21,226 |  |  | $ | 19,488 |
|  |  | $ | 21,226 |  |  | $ | 19,488 |
The following is a summary of the Company’s share of net income (losses) from equity investments accounted for under the equity method of accounting:
| For the three months ended June 30, |  | For the six months ended June 30,
| 2024 |  | 2023 |  | 2024 |  | 2023
Cronos GrowCo | $ | 917 |  |  | $ | 270 |  |  | $ | 2,365 |  |  | $ | (226) |
| $ | 917 |  |  | $ | 270 |  |  | $ | 2,365 |  |  | $ | (226) |
Beginning in the third quarter of 2024, the results of Cronos GrowCo will be consolidated into the results of the Company, and the Company’s investment in Cronos GrowCo will be reclassified as an intercompany transaction and eliminated upon consolidation. For more information, see Note 12 “Subsequent Events.” (b)Other investments Other investments consist of investments in common shares and options of two companies in the cannabis industry. PharmaCann Option On June 14, 2021, the Company purchased an option (the “PharmaCann Option”) to acquire 473,787 shares of Class A Common Stock of PharmaCann, Inc. (“PharmaCann”), a vertically integrated cannabis company in the United States, at an exercise price of $0.0001 per share, representing approximately 10.5% of PharmaCann’s issued and outstanding capital stock on a fully diluted basis as of the date of the PharmaCann Option, for an aggregate purchase price of approximately $110,392. The PharmaCann Option is classified as an investment in an equity security without a readily determinable fair value. The Company measures the PharmaCann Option at cost less accumulated impairment charges, if any, and subsequently adjusted for observable price changes in orderly transactions for the identical or a similar investment of the same issuer. As of June 30, 2024 and December 31, 2023, based on updated information provided by PharmaCann in the second quarter, the Company’s ownership percentage in PharmaCann on a fully diluted basis was approximately 6.2% and 6.6%, respectively. The decrease in the Company’s ownership percentage since acquisition does not materially affect the Company’s rights under the PharmaCann Option. The PharmaCann Option is measured at fair value on a non-recurring basis and is a level 3 asset. See Note 10 “Fair Value Measurements” for more information on the fair value hierarchy. The PharmaCann Option is reported as Other investments on the consolidated balance sheet as of June 30, 2024 and December 31, 2023. During the first and second quarters of 2024, the Company identified adverse forecast changes in the financial performance of PharmaCann as indicators of impairment related to the PharmaCann Option and conducted analyses comparing the PharmaCann Option’s carrying amount to its estimated fair value. The fair value was estimated using the market approach. Under the market approach, the key assumptions are the selected multiples and the discount for lack of marketability. As a result of these analyses, the Company recorded non-cash impairment charges of $12,734 and $12,916 in the first and second quarters of 2024, respectively, as the difference between the carrying amount of the PharmaCann Option and its estimated fair value, in the condensed consolidated statements of net loss and comprehensive loss for the six months ended June 30, 2024. The Company may sell, transfer or dispose of the PharmaCann Option without PharmaCann’s prior written consent, subject to the following conditions: (i) any transferee of any part of the PharmaCann Option must comply with and commit to comply with all regulations issued by a governmental entity applicable to such transferee in all material respects; (ii) any transferee of any part of the PharmaCann Option must agree to be bound by the terms of the Option Purchase Agreement, dated as of June 14, 2021 (the “Option Purchase Agreement”), as a “Purchaser” thereunder; (iii) the Company may not split and/or transfer the PharmaCann Option, in the aggregate, to more than four persons (with certain exceptions); (iv) no transferee may be a Prohibited Assignee (as defined in the Option Purchase Agreement); and (v) subject to certain exceptions, in the event that the Company (or a Permitted Transferee of the whole PharmaCann Option) transfers less than all of the PharmaCann Option to any third party that is not a Permitted Transferee, certain governance and information rights terminate immediately, unless waived by the PharmaCann board of directors in its sole and absolute discretion. Additionally, in the event of an initial underwritten public offering of PharmaCann’s common stock pursuant to an effective registration statement, to the extent that holders of PharmaCann common stock are subject to any lock-up period imposed by the underwriter in connection therewith, the Company will, if applicable, execute a customary lock-up agreement on the same material terms and conditions as the other holders of common stock are subject to or as otherwise agreed between PharmaCann and the Company, subject to certain conditions with respect to the duration of the lock-up period. Vitura Health Limited (formerly known as Cronos Australia) The Company owns approximately 10% of the outstanding common shares of Vitura Health Limited (“Vitura”). The investment is considered an equity security with a readily determinable fair value. Changes in the fair value of the investment are recorded as gain (loss) on revaluation of financial instruments on the condensed consolidated statements of net loss and comprehensive loss. The following table summarizes the Company’s other investments activity:
| As of April 1, 2024 |  | Unrealized loss |  | Impairment charges |  | Foreign exchange effect |  | As of June 30, 2024
PharmaCann | $ | 12,916 |  |  | $ | — |  |  | $ | (12,916) |  |  | $ | — |  |  | $ | — |
Vitura | 6,842 |  |  | (3,755) |  |  | — |  |  | 81 |  |  | 3,168 |
| $ | 19,758 |  |  | $ | (3,755) |  |  | $ | (12,916) |  |  | $ | 81 |  |  | $ | 3,168 |
| As of January 1, 2024 |  | Unrealized loss |  | Impairment charges |  | Foreign exchange effect |  | As of June 30, 2024
PharmaCann | $ | 25,650 |  |  | $ | — |  |  | $ | (25,650) |  |  | $ | — |  |  | $ | — |
Vitura | 9,601 |  |  | (6,097) |  |  | — |  |  | (336) |  |  | 3,168 |
| $ | 35,251 |  |  | $ | (6,097) |  |  | $ | (25,650) |  |  | $ | (336) |  |  | $ | 3,168 |
| As of April 1, 2023 |  | Unrealized gain |  | Impairment charges |  | Foreign exchange effect |  | As of June 30, 2023
PharmaCann | $ | 49,000 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 49,000 |
Vitura | 13,833 |  |  | 5,194 |  |  | — |  |  | (102) |  |  | 18,925 |
| $ | 62,833 |  |  | $ | 5,194 |  |  | $ | — |  |  | $ | (102) |  |  | $ | 67,925 |
| As of January 1, 2023 |  | Unrealized loss |  | Impairment charges |  | Foreign exchange effect |  | As of June 30, 2023
PharmaCann | $ | 49,000 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 49,000 |
Vitura | 21,993 |  |  | (2,729) |  |  | — |  |  | (339) |  |  | 18,925 |
| $ | 70,993 |  |  | $ | (2,729) |  |  | $ | — |  |  | $ | (339) |  |  | $ | 67,925 |

X
- References No definition available. + Details
Name: | us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group. + References Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478156/740-323-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 323 -Publisher FASB -URI https://asc.fasb.org/323/tableOfContent + Details
Name: | us-gaap_EquityMethodInvestmentsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration